

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)


PCT

(10) International Publication Number
WO 01/72352 A2

- (51) International Patent Classification⁷: **A61M 1/00**
- (21) International Application Number: **PCT/US01/08776**
- (22) International Filing Date: 19 March 2001 (19.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/192,221 27 March 2000 (27.03.2000) US
- (71) Applicant (for all designated States except US): **THE CLEVELAND CLINIC FOUNDATION** [US/US]; 9500 Euclid Avenue, Cleveland, OH 44106 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MEDVEDEV, Alexander** [US/US]; 4304 Lander Road, Orange Village, OH 44022 (US). **GOLDING, Leonard, A., R.** [US/US]; 16650 Auburn Road, Auburn Township, OH 44026 (US). **MASSIELLO, Alexander** [US/US]; 10340 Wye Road, Chesterland, OH 44026 (US).
- (74) Agent: **NAUMAN, Timothy, E.**; Fay, Sharpe, Pagan, Minnich & McKee, LLP, 7th floor, 1100 Superior Avenue, Cleveland, OH 44114-2518 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: **CHRONIC PERFORMANCE CONTROL SYSTEM FOR ROTODYNAMIC BLOOD PUMPS**



(57) Abstract: In a left ventricular assist device (LVAD) a rotodynamic blood pump (10) is powered by a brushless DC motor (12). A power supply (14) supplies power to the motor (12). Three feedback channels, one for each of voltage, current, and motor speed lead to a microcontroller or microprocessor (18). The three feedback waveforms are analyzed, and from these waveforms, motor input power, patient heart rate, current pump flow rate, and systemic pressure are determined. The microprocessor (18) then calculates a desired flow rate proportional to the patient heart rate. The microprocessor communicates a new power output to a commutation circuit (16), which regulates power to the motor (12). The pump (10) also includes safety checks that are prioritized over desired pump flow. These include prevention of ventricular suction, low pulsatility, minimum and maximum pump speed, minimum speed-relative pump flow, minimum absolute pump flow, minimum and maximum motor input power.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

CHRONIC PERFORMANCE CONTROL SYSTEM FOR ROTODYNAMIC BLOOD PUMPS

Federal Research Statement

The U.S. Government may have certain rights in this invention pursuant to contract number N01-HV-58159 awarded by the U.S. National Heart, Lung and Blood Institute of the National Institutes of Health.

Background of the Invention

5 The present invention relates to the medical arts. It finds particular application in cardiac assist technologies using, for example, rotodynamic blood pumps, also known as left ventricular assist devices (LVAD) in assisting patients with failing hearts and will be described with particular reference to a centrifugal blood pump. It is to be appreciated that the present invention is also applicable to
10 other types of pumps, such as axial flow pumps, and is not limited to the aforementioned application.

Electrically driven rotodynamic pumps (axial flow, mixed flow and centrifugal) have prospective applications in cardiac assist technologies. A typical cardiac assist system includes the blood pump itself, electrical motor (usually a
15 brushless DC motor integrated into the pump), drive electronics, microprocessor control unit, and an energy source, such as rechargeable batteries. These pumps are used in fully implantable systems for chronic cardiac support. In this case the whole system is located inside the body and there are no drive lines penetrating the skin. For temporary support, and as well as for the bridge-to-transplant application,
20 the pump itself is also located inside the body. However some system components including drive electronics and energy source may be placed outside the patient body.

Both chronic and temporary patient support require controlling the pump performance to satisfy the physiologic needs of the patient while maintaining
25 safe and reliable system operation.

The primary goal for cardiac assist control is to provide an adequate blood pump flow rate for the patient that may depend on various physiological and

psychological factors. Prior systems have pressure sensors, or ECG sensors external to the pump to determine the heart rate and blood pressure of the patient. These systems require extra hardware inside the patient and increase the risk of complication.

5 U.S. Patent No. 5,888,242 to Antaki et al. discloses a rotodynamic ventricular assist pump that uses current measurements and pump rotations per minute (rpm) measurements to test and identify a maximum rpm that will not cause ventricular collapse. The invention described in this patent monitors for a current spike indicative of ventricular collapse, and in response decreases the pump speed.
10 It does this iteratively to achieve a maximum average flow rate. This approach puts unnecessary strain on the heart by continuously depending on this dangerous situation to optimize pump flow.

The present invention provides a new and improved method and apparatus that overcomes the above referenced problems and others.

15

Summary of the Invention

In accordance with one aspect of the present invention, a cardiac assist device is provided. A blood pump is driven by a drive unit powered by a power supply. Three measurable parameters, current, voltage and rotational
20 frequency (or pump speed) each relay their respective sensed waveforms to a controller. A motor winding commutation circuit directed by the controller directs power to the drive unit in response to the sensed waveform.

In accordance with another aspect of the present invention, a method of controlling blood flow with a blood pump is given. A current waveform, voltage
25 waveform, and rotational frequency waveform, are sensed. The sensed information is provided to a blood pump controller which alters operation of the blood pump if necessary.

One advantage of the present invention is its independence of supply voltage variations.

30 Another advantage is that it uses a sensorless approach where no flow or pressure sensors are used.

Another advantage is simple control circuitry.

Another advantage is that it takes into account blood viscosity variations.

35 Yet another advantage resides in the enhanced control flexibility and precision while improving system reliability and effectiveness.

Still further benefits and advantages of the present invention will become apparent to those skilled in the art upon a reading and understanding of the preferred embodiments.

5

Brief Description of the Drawings

The invention may take form in various components and arrangements of components, and in various steps and arrangements of steps. The drawings are only for purposes of illustrating preferred embodiments and are not to be construed as limiting the invention.

10

FIGURE 1 is a graphical representation of targeted pump flow (Q) to heart rate (HR).

FIGURE 2 is a graphical representation of targeted pump flow (L/min) versus a ratio (M) of heart rate (HR) and mean systemic pressure (P).

15

FIGURE 3 is a graphical illustration of a normalized pump pressure-flow curve.

FIGURE 4 is a graphical representation of normalized power plotted against flow.

FIGURE 5 is an illustration of pulse width modulation used to control motor excitation power.

20

FIGURE 6 is a diagrammatic illustration of a left ventricular assist device drive unit in accordance with the present invention.

FIGURE 7 is a graphical representation of blood viscosity versus hematocrit level.

25

FIGURE 8 is a flow diagram of safety checks that prioritizes emergency conditions.

Detailed Description of the Preferred Embodiment

30

There are several possible approaches to setting a required pump performance level matched to patient individual needs. A simple one employs a few levels of fixed pump speed/flows (i.e., low, medium, high) that are set according to patient activity (i.e., sleeping, sitting, walking). Another more flexible approach uses cardiac pacing technology where a separate pacemaker type device controls the pump performance. The present invention, though, proposes methods that employ patient systemic pressure and/or heart rate to define the required pump

flow while using no pressure or ECG type sensors (so-called "sensorless" approach).

Studies have shown that there is an almost linear dependence between healthy human heart rate and cardiac output for different age groups and various activity levels. Therefore, maintaining an appropriate pump flow (Q_{target}) depending on the patient heart rate (HR) is a reasonable objective for the heart assist control algorithm.

It is important that the controlled pump flow response to changes in patient HR be limited by a maximum (Q_{max}) and minimum (Q_{min}) allowed pump flow associated with upper (HR_{max}) and lower (HR_{min}) heart rate limits respectively. In other words, if $HR > HR_{\text{max}}$ then $Q_{\text{target}} = Q_{\text{max}}$; if $HR < HR_{\text{min}}$ then $Q_{\text{target}} = Q_{\text{min}}$. The values of Q_{max} , Q_{min} , HR_{max} and HR_{min} are based on the patient's residual ventricular function, body size and activity level. In the preferred embodiment (see FIGURE 1.) the pump flow demand is proportional to the heart rate:

$$Q_{\text{target}} = C_1 * HR + C_2, \text{ L/min.} \quad (1)$$

where the constants C_1 and C_2 are found using following expressions:

$$C_1 = (Q_{\text{max}} - Q_{\text{min}}) / (HR_{\text{max}} - HR_{\text{min}})$$

$$C_2 = Q_{\text{max}} - C_1 * HR_{\text{max}}$$

A linear dependence between the patient heart rate and the assisting pump flow rate is not the only possible relationship. There is some merit to an argument that the pump flow response can be a non-linear function. Generally, any equation that defines the required pump flow as a function of the patient heart rate can be used.

An alternate approach uses the patient heart rate and an estimated mean systemic pressure P to control the pump flow (see FIGURE 2). The ratio $M = HR/P$ is used as an independent variable that defines the appropriate pump flow:

$$Q_{\text{target}} = f(M). \quad (2)$$

where f is a monotonic function within the specified interval $[M_{\text{min}}, M_{\text{max}}]$. It is also important that the targeted pump flow response to changes in the M ratio be limited by maximum and minimum M values that are defined as follows:

$$M_{\text{max}} = HR_{\text{max}} / P_{\text{min}};$$

$$M_{\text{min}} = HR_{\text{min}} / P_{\text{max}}.$$

Where P_{max} and P_{min} are upper and lower pressure limits respectively. In other words, if $M > M_{\text{max}}$ then $Q_{\text{target}} = Q_{\text{max}}$; if $M < M_{\text{min}}$ then $Q_{\text{target}} = Q_{\text{min}}$. Therefore, by setting M_{max} and M_{min} , a maximum and minimum pump flow

response is defined. Again, the values of Q_{max} , Q_{min} , HR_{max} , HR_{min} as well as P_{max} and P_{min} are defined by the patient's residual ventricular function, body size and activity level. It is to be understood that any function that is monotonic within specified interval $[M_{min}, M_{max}]$ can potentially be employed to define the required pump flow.

The relationship between pump flow and motor input power over a defined pump operating range can be obtained from the steady state power-flow characteristic for a particular pump type. Neglecting fluid inertia this relationship can be used to obtain instantaneous pump flow from a motor power waveform.

Detection of motor power is both a safe and reliable control feedback for motors allowing determination of the instantaneous blood pump flow without direct measurement of flow or pressure drop across the pump. The detected instantaneous flow waveform can be employed to find the pump mean flow. The comparison of the target mean flow value derived from physiologic HR or HR/P input and the current calculated pump mean flow, results in an error signal used to change the pump performance in order to achieve the mean (target) blood flow.

When the rotodynamic blood pump is operated as an LVAD with ventricular cannulation, the motor power, current, speed and pump flow pulsatility correspond with the pulsatility of the ventricular pressure input into the pump inflow cannula. Thus, the heart rate may be found by analyzing the frequency components of the motor current, or speed, or power, or flow waveforms. The fundamental frequency of all of these waveforms is defined by the heart beat rate. This allows heart beat rate detection without direct ECG sensing.

The speed waveform and the calculated pump flow waveform then are used to calculate the pump pressure drop waveform from which the maximum pressure drop across the pump is derived. The maximum pressure drop across the pump is used to estimate mean systemic pressure P . A normalized pump pressure-flow curve is used that is independent of pump operational speed:

$$P_{norm} = \psi(Q_{norm}) \quad (3)$$

where normalized pump pressure $P_{norm} = P / (\sigma * \omega^2)$, normalized flow rate $Q_{norm} = Q / \omega$, σ is the blood density and ω is the pump rotational speed. This normalized pressure-flow dependence (FIGURE 3) allows accurate pump pressure drop calculations if the pump flow and speed is known. This function can be obtained from previous bench pump test data.

The relationship between the motor power and the pump flow rate can be expressed as follows:

$$Q = \varphi (S_{\text{elec}} / \omega^2) \quad (4)$$

where S_{elec} is the average electrical power of the motor in time interval T , ω is the pump rotational speed, and φ is a monotonic function within the pump operating range. For a given motor-pump system φ is obtainable from pump test data using, for example, a curve fit.

Flow versus average power relationships can be found experimentally for a variety of rotodynamic blood pumps driven by brushless DC motors having any type of phase current waveforms. For a properly designed motor-pump system this dependence is close to linear as shown in FIGURE 4.

However a non-linear power-flow dependence can also be derived from pump test data. This has particular advantages over previously described use of motor current and speed to derive pump flow. The method of flow calculations described in U.S. Patent No. 5,888,242 assumes that brushless DC motor has a sinusoidal back electromotive force (EMF) and sinusoidal phase current waveforms. Most brushless DC motors do not have sinusoidal back EMF and current waveforms. Moreover, when pulse width modulation (PWM) is used to control the motor excitation power the motor phase current may be irregular and prone to spiking (FIGURE 5).

The average electrical power consumed by a brushless DC motor is found by:

$$S_{\text{elec}} = v * I \quad (5)$$

where v is the motor driver bus voltage, and I is the motor average (or DC) current within a certain time interval, T .

The time interval T should be small enough to allow proper representation of the pump flow, power and speed pulsatility associated with the heart residual function. On the other hand, T should be large enough to ignore power spikes associated with the motor commutation. This defines the requirements for low-pass filter signal conditioning as well as analog to digital converter (ADC) sampling rate that is faster than $2/T$ samples/sec. This arrangement provides proper representation of the pump performance variation during a cardiac cycle while ignoring power disturbances associated with motor commutation and excitation power control by the PWM. In the preferred embodiment the time interval is

$$120/(NP * \omega_{\text{min}}) < T < 30/HR_{\text{max}}$$

where NP is number of pump motor magnetic poles; ω_{\min} is the minimum pump operating rotational frequency, RPM; HR_{\max} is the maximum considered patient's heart rate, BPM.

Using motor power instead of motor current (the latter was described in U.S. Patent No. 5,888,242 by Antaki et al.) for pump flow calculation means that the calculation is independent of system voltage variations. Voltage variations that occur while LVAD systems are run on portable or implantable batteries can significantly change the current required to maintain the same pump steady state power level. Therefore, the preferred embodiment has a superior accuracy for flow calculations compared to methods that use current to calculate pump flows. This approach also eliminates the need for driver voltage regulation that is necessary if the pump flow rate is calculated using the motor current.

With reference to FIGURE 6, a blood pump 10 is driven by a brushless DC motor 12. In the preferred embodiment, the blood pump 10 is an implanted centrifugal blood pump. Alternately, mixed or axial flow blood pumps can be used. A power supply 14 supplies power to the motor 12 via a motor winding commutation circuit 16. The circuit 16 acts as a power regulator and is controlled by a microprocessor or microcontroller 18.

The microprocessor 18 receives information from three sensors. A current sensor 20 provides a current waveform to the microprocessor 18. The current waveform is the current supplied to the motor 12 by the circuit 16 over a period of time. A voltage sensor 22 provides the microprocessor 18 with a voltage waveform that represents the voltage supplied to the motor 12 over a period of time. A frequency sensor 24 supplies the microprocessor 18 with a frequency waveform that tracks the speed of the motor 12 over a period of time. Preferably, the frequency sensor 24 is a back electromotive force (EMF) or a rotor position sensor such as a Hall effect sensor that calculates a revolutions per minute (RPM) measurement to provide timing for motor winding commutation. Alternately, an optical sensor can be used to track the speed of the motor.

Within a certain time interval (e.g., every ten seconds), the microcontroller continuously receives a signal from the current sensor 20 representing mean DC motor current waveform, a signal from the frequency sensor 24 representing the pump rotational speed waveform, and a signal from the power supply representing the power supply voltage.

Based on these three inputs, the microcontroller 18 calculates a motor input power, S_{elec} , using equation (5); an instantaneous pump flow, Q, from

equation (4); the average pump flow over the time interval; the patient heart rate HR, by counting the number of pulses in any one of the power, current, flow or speed waveforms that are associated with the residual ventricular function or by finding the waveform fundamental frequency; a pump pressure differential, P, using the pump pressure-flow relationship of equation (3) and a required or target pump flow, Q_{target} , for current physiologic conditions according to equation (1) or (2). The microcontroller also analyzes the pump performance and checks for predetermined patient safety conditions using power, speed, flow and pressure waveforms. Finally the microcontroller implements a change in power delivered to the motor as needed in order to first correct any detected operating conditions or if all conditions are met, to match the required flow, Q_{target} .

In case of a software or hardware failure associated with the microcontroller, the winding commutation circuit 16 provides uninterrupted pump performance at the predetermined (motor power) level. Thus, improved reliability is provided with this arrangement.

In the preferred embodiment, the pump motor input power is the only directly controlled parameter. By varying the pump performance through the motor power, a target pump blood flow is maintained based on the derived physiologic HR or HR/P ratio. There are, however, four functional conditions that must be met before implementing any change in motor power to achieve the target pump flow. These conditions, if not met, implement a change in motor power to correct the condition and take priority over motor power changes to achieve target flows.

The first condition is the prevention of ventricular suction. This requires an immediate pumping power reduction if either such condition or prior to the onset of such situation (a pre-suction condition) is detected.

The second condition is related to reverse flow through the pump. An instantaneous reverse flow is avoided in order to achieve proper flow circulation through the pump. If instantaneous reverse flow at any time exceeds a certain limit the controller increases pumping by delivering more power to the motor assuming that the first priority condition is satisfied.

A third condition is the microcontroller response to tachycardia or bradycardia or to errors in the HR calculation. If the calculated HR exceeded preset maximum or minimum values, the controller decreases pumping by delivering less power to the pump motor. The maximum and minimum safe HR in the preferred

embodiment are 180 and 40 bpm respectively but can be adjusted to the needs of the individual patient.

The fourth condition is to ensure that pump operational speed is maintained within a predefined range for ideal system performance. The limits may depend on both patient conditions and pump technical characteristics. In the current embodiment, minimum and maximum allowable speed limits were set at 2200 RPM and 3200 RPM, respectively, but can be adjusted for individual patient needs. Any requested change in power delivered to the motor based on target flow requirements or any of the above priority conditions will not be implemented if they will cause pump speed to exceed these limits.

Prevention of ventricular suction is implemented by detection of a pre-suction condition. In the preferred embodiment, pre-suction detection is based on the assumption that low pump flow pulsatility is associated with a completely unloaded ventricle, low intraventricular pressure and steady state (nonpulsatile) systemic pressure. Any significant increase in pump flow after depulsing the circulation could lead to complete or more likely partial collapse of the ventricle wall into the pump inflow cannula orifice.

The flow pulsatility can be defined as the following:

$$DQ = (Q_{\text{peak}(+)} - Q_{\text{mean}}) / Q_{\text{mean}} \quad (6)$$

where Q_{mean} is the mean flow rate for all cardiac cycles recorded over a given control cycle and $Q_{\text{peak}(+)}$ is the average of the maximum instantaneous pump flow value within each cardiac cycle over the given control cycle. This peak flow is associated with ventricular systole when the pressure across the pump is minimal. DQ values below a predetermined limit are used to detect a pre-suction condition and require an immediate pumping power reduction.

It is understood that there are other ways to determine the pulsatility of a waveform using its extreme and mean values as well as time-based parameters. For example, the following expressions for pump flow pulsatility can also be used to detect a pre-suction conditions:

$$\begin{aligned} DQ_1 &= (Q_{\text{peak}(+)} - Q_{\text{peak}(-)}) / Q_{\text{mean}} , \\ DQ_2 &= (Q_{\text{peak}(+)} - Q_{\text{peak}(-)}) / Q_{\text{peak}(+)} , \\ DQ_3 &= (Q_{\text{mean}} - Q_{\text{peak}(-)}) / Q_{\text{mean}} , \text{ etc.} \end{aligned}$$

where $Q_{\text{peak}(-)}$ is the average of the peak minimum instantaneous flow rates within each cardiac cycle recorded over a given control cycle. This peak minimum flow is

associated with ventricular diastole when the pressure across the pump is maximum.

If suction does occur rapidly before an adequate control response based on low pulsatility limits (DQ), the pump flow will drop significantly due to inflow cannula occlusion. If the pump flow reduces below a predetermined absolute minimum flow Q_{absmin} , complete or significant inflow cannula occlusion is detected and requires an immediate pumping power reduction. The value of Q_{absmin} is adjusted to individual patient physiology.

In the case of partial inflow cannula occlusion, the flow pulsatility may remain high, masking DQ limit detection. However, if the pump flow reduces below a predetermined relative minimum flow $Q_{rel min}$ expected for the current pump operating speed, partial inflow cannula occlusion is detected and again requires an immediate pumping power reduction. The relative minimum flow $Q_{rel min}$ expected for any current pump operating speed is defined as the following:

$$Q_{rel min} = A * (\omega - \omega_0)^n \quad (7)$$

In the preferred embodiment, $A = 1.5$, $\omega_0 = 1.2$ KRPM, $n = 2$, but can be different. If at any given speed within the controller allowed range, the pump flow $Q < Q_{rel min}$ the controller reduces power to the motor until the flow is restored to $Q > Q_{rel min}$.

An additional indicator of either a suction or a pre-suction condition is the absolute value for flow pulsatility defined as the following:

$$absDQ = (Q_{peak(+)} - Q_{peak(-)})$$

where $Q_{peak(+)}$ and $Q_{peak(-)}$ are the average of the peak maximum and peak minimum instantaneous flow rates within each cardiac cycle recorded over a given control cycle. Any absDQ values below a predetermined limit, can be used to detect such conditions and require an immediate pumping power reduction.

The preferred embodiment requires three input variables: motor current waveform, motor speed waveform and power source (driver) voltage, from which motor power, pump flow, ventricular contraction rate and systemic pressure are determined. This removes the technical and reliability problems associated with direct flow, pressure and heart rate sensing. The motor speed output is available in most brushless DC (BLDC) motor drivers; motor current and power supply voltage sensing are also performed within the driver. This brings all required sensing inside the motor controller/driver and simplifies the system configuration significantly. It is to be appreciated that the preferred embodiment is independent of the motor control mode: the motor speed and current as well as the driver voltage may vary during a cardiac cycle or remain constant.

In the preferred embodiment, the current, voltage and speed waveforms are employed to find the heart rate, motor power, mean pump flow and systemic pressure. Therefore the waveform acquiring interval has to be long enough to determine the heart rate and the average pump flow. Assuming that the normal heart rate is unlikely to be less than 60 BPM, a 6-to-12 second time interval for speed, current and voltage waveform recording is reasonable. This is also adequate to meet a required physiologic dynamic response of a patient to changing heart rate, preload and afterload conditions.

Because the instantaneous maximum and minimum peak pump flows have to be calculated using the sensed voltage, current and speed waveforms, signal noise may lead to unacceptable errors which result in improper system functioning. In the preferred embodiment, waveform filtering with low-pass filters is performed on each of the three waveforms before being digitized by analog to digital converters for analysis by the microprocessor.

Derived from equation 4, the steady state power-flow curves can be used for mean, peak, and minimum pump flow calculations. The accuracy of the pump flow calculation using equation (4) is affected by blood viscosity changes. The blood viscosity depends on blood hematocrit level (FIGURE 7). As blood viscosity increases, more motor power is required for pumping at the same blood flow rate. Therefore, for accurate pump flow calculations a correction factor C_h can be added to expression (4):

$$Q = \phi(S/\omega^2) + C_h$$

A correction factor such as a 0.1 L/min per each percent of hematocrit change from a baseline is preferred.

Since the instantaneous pump flow is known, the pump inlet-outlet pressure difference waveform is calculated using the normalized pressure-flow curve (3). The estimated mean systemic arterial pressure is derived as the maximum pump inlet-outlet pressure difference, P and is defined as:

$$P = \max\{P_{\text{norm}} * \omega^n\} \quad (8)$$

This estimate of systemic arterial pressure is used to calculate ($M = HR/P$) and then the required pump flow Q_{target} is calculated using equation (2).

As discussed above, a patient heart rate can be obtained by performing a harmonic analysis, a fast Fourier transform or equivalent analysis, on the motor current waveform. The waveform fundamental frequency corresponds to the heart rate. The required pump flow Q_{target} is calculated using equation (1) or (2).

After the mean pump flow (Q_{mean}) is calculated, the flow pulsatility (DQ) as in equation (6) is found. Also the error between the actual pump flow and the required flow, Q_{target} can be calculated as:

$$\Delta Q = (Q_{\text{Target}} - Q_{\text{mean}}) / Q_{\text{mean}} \quad (9)$$

5 Since all necessary parameters - Q_{mean} , Q_{peak} , Q_{min} , AbsDQ, DQ, ΔQ , and Q_{target} are calculable, logic analysis is performed and a power control signal is produced for each data acquisition interval of six to twelve seconds in the preferred embodiment. With reference to FIGURE 8, the logic analysis starts with the calculations 30 of power, heart rate, flow, pressure, pulsatility, minimum and
10 maximum peak flow, and target flow from the received frequency (ω), current (I), and voltage (V) waveforms 32. The calculated data is then analyzed to see if any of a set of four priority conditions are not met. First, the speed of the motor is monitored to be sure it is within derived parameters 34, 36. If it is greater than the set maximum, ω_{max} , then the power is decreased at step 38 and an alarm may be
15 provided. If the frequency is less than the minimum ω_{min} , power is increased at step 40 and, again, an alarm may be provided.

Second, pulsatility DQ is checked to make sure it is not less than a preset limit DQ_{min} indicating onset of inflow cannula suction at step 42. If it is, then power is decreased as represented at step 44 and an alarm may be triggered. Next,
20 the flow rate is compared to the absolute and relative minimum flow rates for a given speed 54, 56. If $Q < Q_{\text{abs min}}$ or $Q < Q_{\text{rel min}}$, then suction is detected, power decreased and an alarm can be actuated 58, 60.

Third, the calculated HR is compared to maximum and minimum limits for arrhythmia or fibrillation detection 62. If HR is out of preset limits then
25 power is decreased as represented in step 64 an alarm can be actuated.

Fourth, peak minimum flow rate is compared to a pre-determined maximum allowable reverse pump flow 46. If $Q_{\text{peak}(-)} < Q_{\text{min}}$, then power is increased as indicated in the flow chart at 48 and an alarm may be actuated.

Finally, if all of the above priority conditions are met, then the
30 power to the motor can be changed to achieve the target flow based on the relative difference between the actual pump flow and the required flow, ΔQ . If any of the above conditions were not met, then any associated change in pump power level to correct the condition takes priority over that to achieve the target flow, and the control loop begins again.

35 It is to be understood that additional safety and control conditions can also be utilized in the proposed system. For example, if the motor power level

is outside of a predetermined range, an alarm signal is initiated and the system is switched to a safety mode.

The physiologic control algorithm of the present invention uses a "sensorless" approach, i.e., no pressure or flow sensors, and no ECG signal is required. The pump speed, motor voltage, and current waveforms are used for heart rate, pump flow, and patient pressure estimates. The controller analyzes this information and develops a control signal targeting a pump flow that is appropriate to the patient condition. This pump flow is a predetermined function of the patient pressure and/or heart rate and also depends on the size and degree of heart failure of the patient. Several limiting safety conditions and correction factors are involved in the control signal development.

Several significant advantages are attained relative to known arrangements.

First, using the pump flow instead of the pump speed as the control objective advantageously provides a responsive and flexible control system that can automatically adjust the pump performance according to changing patient condition (i.e., enhanced left ventricle contractility due to the heart recovery). This also eliminates the need for the speed stabilizing circuitry (speed control loop) in the motor drive since the speed may vary during the cardiac cycle.

Second, the developed algorithm is applicable to a wide variety of brushless motors driven by currents having waveforms of any shape, rather than being limited to a sine-wave current type of motor. This is advantageous since most brushless motors are not of this type.

Third, the present control algorithm avoids the potentially dangerous situation of ventricular collapse by detecting conditions which precede that event, as opposed to incrementing pump speed until such a situation is detected as suggested by others.

Fourth, the control methodology of the present invention also simplifies the control system by eliminating the need for speed stabilizing circuitry and voltage regulating circuitry.

Fifth, in addition, the control method disclosed herein is independent of voltage variations that can be significant when the pump is powered by batteries.

Sixth, still further, the present control arrangement is deemed more accurate and consequently safer for patients since it recognizes and takes into account patient blood viscosity variations and is also independent of blood flow inertia.

The invention has been described with reference to the preferred embodiment. Modifications and alterations will occur to others upon a reading and understanding of the preceding detailed description. It is intended that the invention be construed as including all such modifications and alterations insofar as
5 they come within the scope of the appended claims or the equivalents thereof.

Having thus described the preferred embodiments, the invention is now claimed to be:

1. A cardiac assist apparatus comprising:
5 a blood pump;
a drive unit for driving the blood pump;
a power supply for supplying power to the drive unit;
a frequency sensor that senses a rotational speed of the blood pump;
a current sensor that senses an average direct current waveform of
10 the drive unit;
a power supply voltage sensor that senses a power supply voltage;
and
a blood pump controller that receives data from the frequency
sensor, current sensor, and the power supply voltage sensor and controls operation
15 of the blood pump in response thereto.
2. The cardiac assist apparatus as set forth in claim 1, wherein the
controller estimates a drive unit input power, a flow rate, a patient heart rate,
pressure and a desired flow rate.
20
3. The cardiac assist apparatus as set forth in claim 1, further
comprising a drive unit winding commutation circuit for relaying the desired flow
rate to the drive unit motor.
- 25 4. The cardiac assist apparatus as set forth in claim 1, wherein the drive
unit includes a brushless DC motor.
5. The cardiac assist apparatus as set forth in claim 1, wherein the
power supply includes at least one rechargeable battery.
30
6. The cardiac assist apparatus as set forth in claim 1, wherein the
frequency sensor includes one of a back EMF, Hall and optical sensor.
7. The cardiac assist apparatus as set forth in claim 1, wherein the
35 controller based on the input information, calculates:
a drive unit input power;

a heart rate;
a pump flow rate; and,
a pressure differential.

5 8. The cardiac assist apparatus as set forth in claim 7, wherein the
controller calculates a new pump flow rate based on the calculated heart rate.

 9. The cardiac assist apparatus as set forth in claim 8, wherein the new
flow rate is within a pre-determined margin.

10

 10. The cardiac assist apparatus as set forth in claim 9, wherein the
margin includes flow rates corresponding to preset maximum and minimum
heartbeats per minute.

15 11. A method of controlling blood flow with a blood pump comprising:
sensing a current waveform of a drive motor of the blood pump;
sensing an input voltage waveform to the drive motor;
sensing a rotational frequency waveform of the drive motor; and
controlling operation of the blood pump in response to the sensing
20 steps.

 12. The method as set forth in claim 11, further including:
calculating a motor input power;
calculating a heart rate;
25 calculating a pump flow rate;
calculating a pump pressure differential; and,
calculating a required pump flow based on current physiological
conditions.

30 13. The method as set forth in claim 12, further including:
analyzing a pump performance to verify that the pump is operating
within predetermined conditions.

 14. The method as set forth in claim 12, wherein the step of calculating
35 the motor input power uses the equation:

$$S_{elec} = v * I$$

where S_{elec} is an average electrical power of the motor in a time interval T , v is the measured voltage, and I is an average current over the time interval T .

15. The method as set forth in claim 14, wherein the step of calculating
5 the heart rate includes analyzing one of the current waveform, input power, rotational frequency, pressure differential and pump flow waveform for a fundamental frequency.

16. The method as set forth in claim 12, wherein the step of calculating
10 the pump pressure differential includes using one of the equation:

$$P_{\text{norm}} = \psi(Q_{\text{norm}})$$

and a look up table, where $P_{\text{norm}} = P/\sigma \cdot \omega^2$, $Q_{\text{norm}} = Q/\omega$, and ω is the pump rotational speed, σ is the blood density.

17. The method as set forth in claim 12, wherein the step of calculating
15 the required pump flow includes one of the equations:

$$Q_{\text{target}} = C_1 * \text{HR} + C_2; \text{ and,}$$

$$Q_{\text{target}} = f(M);$$

where Q_{target} is the desired flow rate, C_1 and C_2 are constants determined by patient
20 heart condition and size, $M = \text{HR}/P$ where P is the pressure and HR is the heart rate.

18. The method as set forth in claim 12, wherein the step of calculating
the required pump flow includes tracking the heart rate and basing the flow rate on
25 the heart rate.

19. The method as set forth in claim 13, wherein the predetermined
conditions include:

30 a minimum flow rate;
a maximum flow rate;
a minimum pulsatility;
a minimum pump rotational speed; and,
a maximum pump rotational speed.

20. The method as set forth in claim 12, further including reverting to a
35 pre-selected default pump rotational speed in the event of a controller failure.

21. The method as set forth in claim 12, further including reverting to a pre-selected default motor input power in the event of a controller failure.

5 22. The method as set forth in claim 12, further including reverting to a pre-selected default PWM duty cycle in the event of a controller failure.

23. The method as set forth in claim 19 wherein the safety conditions include:

10 absolute minimum flow rate, and
relative minimum flow rate.

24. The method as set forth in claim 23 comprising the further step of calculating the relative minimum flow rate as

15
$$Q_{rel\ min} = A * (\omega - \omega_0)^n.$$

25. The method as set in claim 23, further including reverting to a pre-selected default power level decrease in response to detecting ventricular suction.


20 26. The method as set forth in claim 12, wherein the step of calculating the pump flow includes using one of the equation:

$$Q = \varphi(S/\omega^2)$$

and a look up table, where $S = V * I$, S is average electrical power, V is motor driven bus voltage, I is motor average current within a certain time interval, and ω is the
25 pump rotational speed.

$$C1 = (Q_{\max} - Q_{\min}) / (HR_{\max} - HR_{\min})$$


$$C2 = Q_{\max} - C1 * HR_{\max}$$



Ref: AHA Journal "Circulation", Vol 69, No.2, Feb, 1984

Fig. 1

PUMP FLOW (L/min) vs M = HR / Delta P



HR (BPM)	60	90	120	60	90	120	60	90	120
Delta P (mmHg)	120	120	120	90	90	90	60	60	60
M	.5	.75	1	.67	1	1.33	1	1.5	2

Fig. 2.




FIGURE 3




Fig. 4.





Fig. 5




Fig. 6




Fig. 7




Fig. 8

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72352 A3

(51) International Patent Classification⁷: **A61M 1/10**

MASSIELLO, Alexander [US/US]; 10340 Wye Road,
Chesterland, OH 44026 (US).

(21) International Application Number: **PCT/US01/08776**

(74) Agent: **GEORGE, Kenneth, P.**; Amster, Rothstein &
Ebenstein, 90 Park Avenue, New York, NY 10016 (US).

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
60/192,221 27 March 2000 (27.03.2000) US

(71) Applicant (for all designated States except US): **THE
CLEVELAND CLINIC FOUNDATION** [US/US]; 9500
Euclid Avenue, Cleveland, OH 44106 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **MEDVEDEV,
Alexander** [US/US]; 4304 Lander Road, Orange Village,
OH 44022 (US). **GOLDING, Leonard, A., R.** [US/US];
16650 Auburn Road, Auburn Township, OH 44026 (US).

Published:

— with international search report

[Continued on next page]

(54) Title: CHRONIC PERFORMANCE CONTROL SYSTEM FOR ROTODYNAMIC BLOOD PUMPS



(57) Abstract: In a left ventricular assist device (LVAD) a rotodynamic blood pump (10) is powered by a brushless DC motor (12). A power supply (14) supplies power to the motor (12). Three feedback channels, one for each of voltage, current, and motor speed lead to a microcontroller or microprocessor (18). The three feedback waveforms are analyzed, and from these waveforms, motor input power, patient heart rate, current pump flow rate, and systemic pressure are determined. The microprocessor (18) then calculates a desired flow rate proportional to the patient heart rate. The microprocessor communicates a new power output to a commutation circuit (16), which regulates power to the motor (12). The pump (10) also includes safety checks that are prioritized over desired pump flow. These include prevention of ventricular suction, low pulsatility, minimum and maximum pump speed, minimum speed-relative pump flow, minimum absolute pump flow, minimum and maximum motor input power.



(88) Date of publication of the international search report:
18 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/08776

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61M1/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 711 753 A (CLARK RICHARD E ET AL) 27 January 1998 (1998-01-27) column 11, line 49 -column 13, line 7 column 14, line 45 - line 47 figures 13,14	1,4,6,11
A	WO 99 17819 A (MICROMED TECHNOLOGY INC) 15 April 1999 (1999-04-15) page 5, line 14 -page 6, line 11 page 7, line 10 -page 9, line 9 page 15, line 20 - line 28 figures 3,6	1,11
A	DE 196 34 180 A (NTN TOYO BEARING CO LTD) 27 February 1997 (1997-02-27) column 2, line 57 -column 3, line 58 column 4, line 52 -column 5, line 49 figures 1-5	1,11

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

2 October 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schönleben, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/08776

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5711753	A	27-01-1998	US 6162167 A	19-12-2000
			AU 699959 B2	17-12-1998
			AU 3513495 A	10-11-1995
			AU 718838 B2	20-04-2000
			AU 6599798 A	02-07-1998
			CA 2165166 A1	26-10-1995
			EP 0708664 A1	01-05-1996
			JP 9502375 T	11-03-1997
			WO 9528185 A1	26-10-1995
WO 9917819	A	15-04-1999	AU 9787498 A	27-04-1999
			EP 1019117 A1	19-07-2000
			TW 404842 B	11-09-2000
			WO 9917819 A1	15-04-1999
			US 6183412 B1	06-02-2001
DE 19634180	A	27-02-1997	JP 9056812 A	04-03-1997
			DE 19634180 A1	27-02-1997
			US 6129660 A	10-10-2000

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/072352 A3

(51) International Patent Classification⁷: **A61M 1/10**

(21) International Application Number: PCT/US01/08776

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/192,221 27 March 2000 (27.03.2000) US

(71) Applicant (for all designated States except US): **THE CLEVELAND CLINIC FOUNDATION** [US/US]; 9500 Euclid Avenue, Cleveland, OH 44106 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEDVEDEV, Alexander** [US/US]; 4304 Lander Road, Orange Village,

OH 44022 (US). **GOLDING, Leonard, A., R.** [US/US]; 16650 Auburn Road, Auburn Township, OH 44026 (US). **MASSIELLO, Alexander** [US/US]; 10340 Wye Road, Chesterland, OH 44026 (US).


(74) Agent: **GEORGE, Kenneth, P.**; Amster, Rothstein & Ebenstein, 90 Park Avenue, New York, NY 10016 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CHRONIC PERFORMANCE CONTROL SYSTEM FOR ROTODYNAMIC BLOOD PUMPS



(57) Abstract: In a left ventricular assist device (LVAD) a rotodynamic blood pump (10) is powered by a brushless DC motor (12). A power supply (14) supplies power to the motor (12). Three feedback channels, one for each of voltage, current, and motor speed lead to a microcontroller or microprocessor (18). The three feedback waveforms are analyzed, and from these waveforms, motor input power, patient heart rate, current pump flow rate, and systemic pressure are determined. The microprocessor (18) then calculates a desired flow rate proportional to the patient heart rate. The microprocessor communicates a new power output to a commutation circuit (16), which regulates power to the motor (12). The pump (10) also includes safety checks that are prioritized over desired pump flow. These include prevention of ventricular suction, low pulsatility, minimum and maximum pump speed, minimum speed-relative pump flow, minimum absolute pump flow, minimum and maximum motor input power.



Published:

with international search report

(88) Date of publication of the international search report:

18 April 2002

(48) Date of publication of this corrected version:

19 December 2002

(15) Information about Correction:

see PCT Gazette No. 51/2002 of 19 December 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

CHRONIC PERFORMANCE CONTROL SYSTEM FOR ROTODYNAMIC BLOOD PUMPS

Federal Research Statement

The U.S. Government may have certain rights in this invention pursuant to contract number N01-HV-58159 awarded by the U.S. National Heart, Lung and Blood Institute of the National Institutes of Health.

Background of the Invention

5 The present invention relates to the medical arts. It finds particular application in cardiac assist technologies using, for example, rotodynamic blood pumps, also known as left ventricular assist devices (LVAD) in assisting patients with failing hearts and will be described with particular reference to a centrifugal blood pump. It is to be appreciated that the present invention is also applicable to
10 other types of pumps, such as axial flow pumps, and is not limited to the aforementioned application.

Electrically driven rotodynamic pumps (axial flow, mixed flow and centrifugal) have prospective applications in cardiac assist technologies. A typical cardiac assist system includes the blood pump itself, electrical motor (usually a
15 brushless DC motor integrated into the pump), drive electronics, microprocessor control unit, and an energy source, such as rechargeable batteries. These pumps are used in fully implantable systems for chronic cardiac support. In this case the whole system is located inside the body and there are no drive lines penetrating the skin. For temporary support, and as well as for the bridge-to-transplant application,
20 the pump itself is also located inside the body. However some system components including drive electronics and energy source may be placed outside the patient body.

Both chronic and temporary patient support require controlling the pump performance to satisfy the physiologic needs of the patient while maintaining
25 safe and reliable system operation.

The primary goal for cardiac assist control is to provide an adequate blood pump flow rate for the patient that may depend on various physiological and

psychological factors. Prior systems have pressure sensors, or ECG sensors external to the pump to determine the heart rate and blood pressure of the patient. These systems require extra hardware inside the patient and increase the risk of complication.

- 5 U.S. Patent No. 5,888,242 to Antaki et al. discloses a rotodynamic ventricular assist pump that uses current measurements and pump rotations per minute (rpm) measurements to test and identify a maximum rpm that will not cause ventricular collapse. The invention described in this patent monitors for a current spike indicative of ventricular collapse, and in response decreases the pump speed.
- 10 It does this iteratively to achieve a maximum average flow rate. This approach puts unnecessary strain on the heart by continuously depending on this dangerous situation to optimize pump flow.

The present invention provides a new and improved method and apparatus that overcomes the above referenced problems and others.

15

Summary of the Invention

- In accordance with one aspect of the present invention, a cardiac assist device is provided. A blood pump is driven by a drive unit powered by a power supply. Three measurable parameters, current, voltage and rotational
- 20 frequency (or pump speed) each relay their respective sensed waveforms to a controller. A motor winding commutation circuit directed by the controller directs power to the drive unit in response to the sensed waveform.

- In accordance with another aspect of the present invention, a method of controlling blood flow with a blood pump is given. A current waveform, voltage
- 25 waveform, and rotational frequency waveform, are sensed. The sensed information is provided to a blood pump controller which alters operation of the blood pump if necessary.

One advantage of the present invention is its independence of supply voltage variations.

- 30 Another advantage is that it uses a sensorless approach where no flow or pressure sensors are used.

Another advantage is simple control circuitry.

Another advantage is that it takes into account blood viscosity variations.

- 35 Yet another advantage resides in the enhanced control flexibility and precision while improving system reliability and effectiveness.

Still further benefits and advantages of the present invention will become apparent to those skilled in the art upon a reading and understanding of the preferred embodiments.

5

Brief Description of the Drawings

The invention may take form in various components and arrangements of components, and in various steps and arrangements of steps. The drawings are only for purposes of illustrating preferred embodiments and are not to be construed as limiting the invention.

10

FIGURE 1 is a graphical representation of targeted pump flow (Q) to heart rate (HR).

FIGURE 2 is a graphical representation of targeted pump flow (L/min) versus a ratio (M) of heart rate (HR) and mean systemic pressure (P).

15

FIGURE 3 is a graphical illustration of a normalized pump pressure-flow curve.

FIGURE 4 is a graphical representation of normalized power plotted against flow.

FIGURE 5 is an illustration of pulse width modulation used to control motor excitation power.

20

FIGURE 6 is a diagrammatic illustration of a left ventricular assist device drive unit in accordance with the present invention.

FIGURE 7 is a graphical representation of blood viscosity versus hematocrit level.

25

FIGURE 8 is a flow diagram of safety checks that prioritizes emergency conditions.

Detailed Description of the Preferred Embodiment

30

There are several possible approaches to setting a required pump performance level matched to patient individual needs. A simple one employs a few levels of fixed pump speed/flows (i.e., low, medium, high) that are set according to patient activity (i.e., sleeping, sitting, walking). Another more flexible approach uses cardiac pacing technology where a separate pacemaker type device controls the pump performance. The present invention, though, proposes methods that employ patient systemic pressure and/or heart rate to define the required pump

flow while using no pressure or ECG type sensors (so-called "sensorless" approach).

Studies have shown that there is an almost linear dependence between healthy human heart rate and cardiac output for different age groups and various activity levels. Therefore, maintaining an appropriate pump flow (Q_{target}) depending on the patient heart rate (HR) is a reasonable objective for the heart assist control algorithm.

It is important that the controlled pump flow response to changes in patient HR be limited by a maximum (Q_{max}) and minimum (Q_{min}) allowed pump flow associated with upper (HR_{max}) and lower (HR_{min}) heart rate limits respectively. In other words, if $HR > HR_{\text{max}}$ then $Q_{\text{target}} = Q_{\text{max}}$; if $HR < HR_{\text{min}}$ then $Q_{\text{target}} = Q_{\text{min}}$. The values of Q_{max} , Q_{min} , HR_{max} and HR_{min} are based on the patient's residual ventricular function, body size and activity level. In the preferred embodiment (see FIGURE 1.) the pump flow demand is proportional to the heart rate:

$$Q_{\text{target}} = C_1 * HR + C_2, \text{ L/min.} \quad (1)$$

where the constants C_1 and C_2 are found using following expressions:

$$C_1 = (Q_{\text{max}} - Q_{\text{min}}) / (HR_{\text{max}} - HR_{\text{min}})$$

$$C_2 = Q_{\text{max}} - C_1 * HR_{\text{max}}$$

A linear dependence between the patient heart rate and the assisting pump flow rate is not the only possible relationship. There is some merit to an argument that the pump flow response can be a non-linear function. Generally, any equation that defines the required pump flow as a function of the patient heart rate can be used.

An alternate approach uses the patient heart rate and an estimated mean systemic pressure P to control the pump flow (see FIGURE 2). The ratio $M = HR/P$ is used as an independent variable that defines the appropriate pump flow:

$$Q_{\text{target}} = f(M). \quad (2)$$

where f is a monotonic function within the specified interval $[M_{\text{min}}, M_{\text{max}}]$. It is also important that the targeted pump flow response to changes in the M ratio be limited by maximum and minimum M values that are defined as follows:

$$M_{\text{max}} = HR_{\text{max}} / P_{\text{min}};$$

$$M_{\text{min}} = HR_{\text{min}} / P_{\text{max}}.$$

Where P_{max} and P_{min} are upper and lower pressure limits respectively. In other words, if $M > M_{\text{max}}$ then $Q_{\text{target}} = Q_{\text{max}}$; if $M < M_{\text{min}}$ then $Q_{\text{target}} = Q_{\text{min}}$. Therefore, by setting M_{max} and M_{min} , a maximum and minimum pump flow

response is defined. Again, the values of Q_{max} , Q_{min} , HR_{max} , HR_{min} as well as P_{max} and P_{min} are defined by the patient's residual ventricular function, body size and activity level. It is to be understood that any function that is monotonic within specified interval $[M_{min}, M_{max}]$ can potentially be employed to define the required pump flow.

The relationship between pump flow and motor input power over a defined pump operating range can be obtained from the steady state power-flow characteristic for a particular pump type. Neglecting fluid inertia this relationship can be used to obtain instantaneous pump flow from a motor power waveform.

Detection of motor power is both a safe and reliable control feedback for motors allowing determination of the instantaneous blood pump flow without direct measurement of flow or pressure drop across the pump. The detected instantaneous flow waveform can be employed to find the pump mean flow. The comparison of the target mean flow value derived from physiologic HR or HR/P input and the current calculated pump mean flow, results in an error signal used to change the pump performance in order to achieve the mean (target) blood flow.

When the rotodynamic blood pump is operated as an LVAD with ventricular cannulation, the motor power, current, speed and pump flow pulsatility correspond with the pulsatility of the ventricular pressure input into the pump inflow cannula. Thus, the heart rate may be found by analyzing the frequency components of the motor current, or speed, or power, or flow waveforms. The fundamental frequency of all of these waveforms is defined by the heart beat rate. This allows heart beat rate detection without direct ECG sensing.

The speed waveform and the calculated pump flow waveform then are used to calculate the pump pressure drop waveform from which the maximum pressure drop across the pump is derived. The maximum pressure drop across the pump is used to estimate mean systemic pressure P . A normalized pump pressure-flow curve is used that is independent of pump operational speed:

$$P_{norm} = \psi(Q_{norm}) \quad (3)$$

where normalized pump pressure $P_{norm} = P / (\sigma * \omega^2)$, normalized flow rate $Q_{norm} = Q / \omega$, σ is the blood density and ω is the pump rotational speed. This normalized pressure-flow dependence (FIGURE 3) allows accurate pump pressure drop calculations if the pump flow and speed is known. This function can be obtained from previous bench pump test data.

The relationship between the motor power and the pump flow rate can be expressed as follows:

where S_{elec} is the average electrical power of the motor in time interval T , ω is the pump rotational speed, and ϕ is a monotonic function within the pump operating range. For a given motor-pump system ϕ is obtainable from pump test data using, for example, a curve fit.

Flow versus average power relationships can be found experimentally for a variety of rotodynamic blood pumps driven by brushless DC motors having any type of phase current waveforms. For a properly designed motor-pump system this dependence is close to linear as shown in FIGURE 4. However a non-linear power-flow dependence can also be derived from pump test data. This has particular advantages over previously described use of motor current and speed to derive pump flow. The method of flow calculations described in U.S. Patent No. 5,888,242 assumes that brushless DC motor has a sinusoidal back electromotive force (EMF) and sinusoidal phase current waveforms. Most brushless DC motors do not have sinusoidal back EMF and current waveforms. Moreover, when pulse width modulation (PWM) is used to control the motor excitation power the motor phase current may be irregular and prone to spiking (FIGURE 5).

The average electrical power consumed by a brushless DC motor is found by:

$$S_{elec} = v * I \quad (5)$$

where v is the motor driver bus voltage, and I is the motor average (or DC) current within a certain time interval, T .

The time interval T should be small enough to allow proper representation of the pump flow, power and speed pulsatility associated with the heart residual function. On the other hand, T should be large enough to ignore power spikes associated with the motor commutation. This defines the requirements for low-pass filter signal conditioning as well as analog to digital converter (ADC) sampling rate that is faster than $2/T$ samples/sec. This arrangement provides proper representation of the pump performance variation during a cardiac cycle while ignoring power disturbances associated with motor commutation and excitation power control by the PWM. In the preferred embodiment the time interval is

$$120/(NP * \omega_{min}) < T < 30/HR_{max}$$

where NP is number of pump motor magnetic poles; ω_{\min} is the minimum pump operating rotational frequency, RPM; HR_{\max} is the maximum considered patient's heart rate, BPM.

Using motor power instead of motor current (the latter was described in U.S. Patent No. 5,888,242 by Antaki et al.) for pump flow calculation means that the calculation is independent of system voltage variations. Voltage variations that occur while LVAD systems are run on portable or implantable batteries can significantly change the current required to maintain the same pump steady state power level. Therefore, the preferred embodiment has a superior accuracy for flow calculations compared to methods that use current to calculate pump flows. This approach also eliminates the need for driver voltage regulation that is necessary if the pump flow rate is calculated using the motor current.

With reference to FIGURE 6, a blood pump 10 is driven by a brushless DC motor 12. In the preferred embodiment, the blood pump 10 is an implanted centrifugal blood pump. Alternately, mixed or axial flow blood pumps can be used. A power supply 14 supplies power to the motor 12 via a motor winding commutation circuit 16. The circuit 16 acts as a power regulator and is controlled by a microprocessor or microcontroller 18.

The microprocessor 18 receives information from three sensors. A current sensor 20 provides a current waveform to the microprocessor 18. The current waveform is the current supplied to the motor 12 by the circuit 16 over a period of time. A voltage sensor 22 provides the microprocessor 18 with a voltage waveform that represents the voltage supplied to the motor 12 over a period of time. A frequency sensor 24 supplies the microprocessor 18 with a frequency waveform that tracks the speed of the motor 12 over a period of time. Preferably, the frequency sensor 24 is a back electromotive force (EMF) or a rotor position sensor such as a Hall effect sensor that calculates a revolutions per minute (RPM) measurement to provide timing for motor winding commutation. Alternately, an optical sensor can be used to track the speed of the motor.

Within a certain time interval (e.g., every ten seconds), the microcontroller continuously receives a signal from the current sensor 20 representing mean DC motor current waveform, a signal from the frequency sensor 24 representing the pump rotational speed waveform, and a signal from the power supply representing the power supply voltage.

Based on these three inputs, the microcontroller 18 calculates a motor input power, S_{elec} , using equation (5); an instantaneous pump flow, Q, from

equation (4); the average pump flow over the time interval; the patient heart rate HR, by counting the number of pulses in any one of the power, current, flow or speed waveforms that are associated with the residual ventricular function or by finding the waveform fundamental frequency; a pump pressure differential, P, using the pump pressure-flow relationship of equation (3) and a required or target pump flow, Q_{target} , for current physiologic conditions according to equation (1) or (2). The microcontroller also analyzes the pump performance and checks for predetermined patient safety conditions using power, speed, flow and pressure waveforms. Finally the microcontroller implements a change in power delivered to the motor as needed in order to first correct any detected operating conditions or if all conditions are met, to match the required flow, Q_{target} .

In case of a software or hardware failure associated with the microcontroller, the winding commutation circuit 16 provides uninterrupted pump performance at the predetermined (motor power) level. Thus, improved reliability is provided with this arrangement.

In the preferred embodiment, the pump motor input power is the only directly controlled parameter. By varying the pump performance through the motor power, a target pump blood flow is maintained based on the derived physiologic HR or HR/P ratio. There are, however, four functional conditions that must be met before implementing any change in motor power to achieve the target pump flow. These conditions, if not met, implement a change in motor power to correct the condition and take priority over motor power changes to achieve target flows.

The first condition is the prevention of ventricular suction. This requires an immediate pumping power reduction if either such condition or prior to the onset of such situation (a pre-suction condition) is detected.

The second condition is related to reverse flow through the pump. An instantaneous reverse flow is avoided in order to achieve proper flow circulation through the pump. If instantaneous reverse flow at any time exceeds a certain limit the controller increases pumping by delivering more power to the motor assuming that the first priority condition is satisfied.

A third condition is the microcontroller response to tachycardia or bradycardia or to errors in the HR calculation. If the calculated HR exceeded preset maximum or minimum values, the controller decreases pumping by delivering less power to the pump motor. The maximum and minimum safe HR in the preferred

embodiment are 180 and 40 bpm respectively but can be adjusted to the needs of the individual patient.

The fourth condition is to ensure that pump operational speed is maintained within a predefined range for ideal system performance. The limits may depend on both patient conditions and pump technical characteristics. In the current embodiment, minimum and maximum allowable speed limits were set at 2200 RPM and 3200 RPM, respectively, but can be adjusted for individual patient needs. Any requested change in power delivered to the motor based on target flow requirements or any of the above priority conditions will not be implemented if they will cause pump speed to exceed these limits.

Prevention of ventricular suction is implemented by detection of a pre-suction condition. In the preferred embodiment, pre-suction detection is based on the assumption that low pump flow pulsatility is associated with a completely unloaded ventricle, low intraventricular pressure and steady state (nonpulsatile) systemic pressure. Any significant increase in pump flow after depulsing the circulation could lead to complete or more likely partial collapse of the ventricle wall into the pump inflow cannula orifice.

The flow pulsatility can be defined as the following:

$$DQ = (Q_{\text{peak}(+)} - Q_{\text{mean}}) / Q_{\text{mean}} \quad (6)$$

where Q_{mean} is the mean flow rate for all cardiac cycles recorded over a given control cycle and $Q_{\text{peak}(+)}$ is the average of the maximum instantaneous pump flow value within each cardiac cycle over the given control cycle. This peak flow is associated with ventricular systole when the pressure across the pump is minimal. DQ values below a predetermined limit are used to detect a pre-suction condition and require an immediate pumping power reduction.

It is understood that there are other ways to determine the pulsatility of a waveform using its extreme and mean values as well as time-based parameters. For example, the following expressions for pump flow pulsatility can also be used to detect a pre-suction conditions:

$$\begin{aligned} DQ_1 &= (Q_{\text{peak}(+)} - Q_{\text{peak}(-)}) / Q_{\text{mean}} , \\ DQ_2 &= (Q_{\text{peak}(+)} - Q_{\text{peak}(-)}) / Q_{\text{peak}(+)} , \\ DQ_3 &= (Q_{\text{mean}} - Q_{\text{peak}(-)}) / Q_{\text{mean}} , \text{ etc.} \end{aligned}$$

where $Q_{\text{peak}(-)}$ is the average of the peak minimum instantaneous flow rates within each cardiac cycle recorded over a given control cycle. This peak minimum flow is

associated with ventricular diastole when the pressure across the pump is maximum.

If suction does occur rapidly before an adequate control response based on low pulsatility limits (DQ), the pump flow will drop significantly due to inflow cannula occlusion. If the pump flow reduces below a predetermined absolute minimum flow Q_{absmin} , complete or significant inflow cannula occlusion is detected and requires an immediate pumping power reduction. The value of Q_{absmin} is adjusted to individual patient physiology.

In the case of partial inflow cannula occlusion, the flow pulsatility may remain high, masking DQ limit detection. However, if the pump flow reduces below a predetermined relative minimum flow $Q_{rel min}$ expected for the current pump operating speed, partial inflow cannula occlusion is detected and again requires an immediate pumping power reduction. The relative minimum flow $Q_{rel min}$ expected for any current pump operating speed is defined as the following:

$$Q_{rel min} = A * (\omega - \omega_0)^n \quad (7)$$

In the preferred embodiment, $A = 1.5$, $\omega_0 = 1.2$ KRPM, $n = 2$, but can be different. If at any given speed within the controller allowed range, the pump flow $Q < Q_{rel min}$ the controller reduces power to the motor until the flow is restored to $Q > Q_{rel min}$.

An additional indicator of either a suction or a pre-suction condition is the absolute value for flow pulsatility defined as the following:

$$absDQ = (Q_{peak(+)} - Q_{peak(-)})$$

where $Q_{peak(+)}$ and $Q_{peak(-)}$ are the average of the peak maximum and peak minimum instantaneous flow rates within each cardiac cycle recorded over a given control cycle. Any absDQ values below a predetermined limit, can be used to detect such conditions and require an immediate pumping power reduction.

The preferred embodiment requires three input variables: motor current waveform, motor speed waveform and power source (driver) voltage, from which motor power, pump flow, ventricular contraction rate and systemic pressure are determined. This removes the technical and reliability problems associated with direct flow, pressure and heart rate sensing. The motor speed output is available in most brushless DC (BLDC) motor drivers; motor current and power supply voltage sensing are also performed within the driver. This brings all required sensing inside the motor controller/driver and simplifies the system configuration significantly. It is to be appreciated that the preferred embodiment is independent of the motor control mode: the motor speed and current as well as the driver voltage may vary during a cardiac cycle or remain constant.

In the preferred embodiment, the current, voltage and speed waveforms are employed to find the heart rate, motor power, mean pump flow and systemic pressure. Therefore the waveform acquiring interval has to be long enough to determine the heart rate and the average pump flow. Assuming that the normal heart rate is unlikely to be less than 60 BPM, a 6-to-12 second time interval for speed, current and voltage waveform recording is reasonable. This is also adequate to meet a required physiologic dynamic response of a patient to changing heart rate, preload and afterload conditions.

Because the instantaneous maximum and minimum peak pump flows have to be calculated using the sensed voltage, current and speed waveforms, signal noise may lead to unacceptable errors which result in improper system functioning. In the preferred embodiment, waveform filtering with low-pass filters is performed on each of the three waveforms before being digitized by analog to digital converters for analysis by the microprocessor.

Derived from equation 4, the steady state power-flow curves can be used for mean, peak, and minimum pump flow calculations. The accuracy of the pump flow calculation using equation (4) is affected by blood viscosity changes. The blood viscosity depends on blood hematocrit level (FIGURE 7). As blood viscosity increases, more motor power is required for pumping at the same blood flow rate. Therefore, for accurate pump flow calculations a correction factor C_h can be added to expression (4):

$$Q = \phi(S/\omega^2) + C_h$$

A correction factor such as a 0.1 L/min per each percent of hematocrit change from a baseline is preferred.

Since the instantaneous pump flow is known, the pump inlet-outlet pressure difference waveform is calculated using the normalized pressure-flow curve (3). The estimated mean systemic arterial pressure is derived as the maximum pump inlet-outlet pressure difference, P and is defined as:

$$P = \max\{P_{\text{norm}} * \omega^n\} \quad (8)$$

This estimate of systemic arterial pressure is used to calculate ($M = HR/P$) and then the required pump flow Q_{target} is calculated using equation (2).

As discussed above, a patient heart rate can be obtained by performing a harmonic analysis, a fast Fourier transform or equivalent analysis, on the motor current waveform. The waveform fundamental frequency corresponds to the heart rate. The required pump flow Q_{target} is calculated using equation (1) or (2).

After the mean pump flow (Q_{mean}) is calculated, the flow pulsatility (DQ) as in equation (6) is found. Also the error between the actual pump flow and the required flow, Q_{target} can be calculated as:

$$\Delta Q = (Q_{\text{Target}} - Q_{\text{mean}}) / Q_{\text{mean}} \quad (9)$$

5 Since all necessary parameters - Q_{mean} , Q_{peak} , Q_{min} , AbsDQ, DQ, ΔQ , and Q_{target} are calculable, logic analysis is performed and a power control signal is produced for each data acquisition interval of six to twelve seconds in the preferred embodiment. With reference to FIGURE 8, the logic analysis starts with the calculations 30 of power, heart rate, flow, pressure, pulsatility, minimum and
10 maximum peak flow, and target flow from the received frequency (ω), current (I), and voltage (V) waveforms 32. The calculated data is then analyzed to see if any of a set of four priority conditions are not met. First, the speed of the motor is monitored to be sure it is within derived parameters 34, 36. If it is greater than the set maximum, ω_{max} , then the power is decreased at step 38 and an alarm may be
15 provided. If the frequency is less than the minimum ω_{min} , power is increased at step 40 and, again, an alarm may be provided.

Second, pulsatility DQ is checked to make sure it is not less than a preset limit DQ_{min} indicating onset of inflow cannula suction at step 42. If it is, then power is decreased as represented at step 44 and an alarm may be triggered. Next,
20 the flow rate is compared to the absolute and relative minimum flow rates for a given speed 54, 56. If $Q < Q_{\text{abs min}}$ or $Q < Q_{\text{rel min}}$, then suction is detected, power decreased and an alarm can be actuated 58, 60.

Third, the calculated HR is compared to maximum and minimum limits for arrhythmia or fibrillation detection 62. If HR is out of preset limits then
25 power is decreased as represented in step 64 an alarm can be actuated.

Fourth, peak minimum flow rate is compared to a pre-determined maximum allowable reverse pump flow 46. If $Q_{\text{peak(-)}} < Q_{\text{min}}$, then power is increased as indicated in the flow chart at 48 and an alarm may be actuated.

Finally, if all of the above priority conditions are met, then the
30 power to the motor can be changed to achieve the target flow based on the relative difference between the actual pump flow and the required flow, ΔQ . If any of the above conditions were not met, then any associated change in pump power level to correct the condition takes priority over that to achieve the target flow, and the control loop begins again.

35 It is to be understood that additional safety and control conditions can also be utilized in the proposed system. For example, if the motor power level

is outside of a predetermined range, an alarm signal is initiated and the system is switched to a safety mode.

The physiologic control algorithm of the present invention uses a "sensorless" approach, i.e., no pressure or flow sensors, and no ECG signal is required. The pump speed, motor voltage, and current waveforms are used for heart rate, pump flow, and patient pressure estimates. The controller analyzes this information and develops a control signal targeting a pump flow that is appropriate to the patient condition. This pump flow is a predetermined function of the patient pressure and/or heart rate and also depends on the size and degree of heart failure of the patient. Several limiting safety conditions and correction factors are involved in the control signal development.

Several significant advantages are attained relative to known arrangements.

First, using the pump flow instead of the pump speed as the control objective advantageously provides a responsive and flexible control system that can automatically adjust the pump performance according to changing patient condition (i.e., enhanced left ventricle contractility due to the heart recovery). This also eliminates the need for the speed stabilizing circuitry (speed control loop) in the motor drive since the speed may vary during the cardiac cycle.

Second, the developed algorithm is applicable to a wide variety of brushless motors driven by currents having waveforms of any shape, rather than being limited to a sine-wave current type of motor. This is advantageous since most brushless motors are not of this type.

Third, the present control algorithm avoids the potentially dangerous situation of ventricular collapse by detecting conditions which precede that event, as opposed to incrementing pump speed until such a situation is detected as suggested by others.

Fourth, the control methodology of the present invention also simplifies the control system by eliminating the need for speed stabilizing circuitry and voltage regulating circuitry.

Fifth, in addition, the control method disclosed herein is independent of voltage variations that can be significant when the pump is powered by batteries.

Sixth, still further, the present control arrangement is deemed more accurate and consequently safer for patients since it recognizes and takes into account patient blood viscosity variations and is also independent of blood flow inertia.

The invention has been described with reference to the preferred embodiment. Modifications and alterations will occur to others upon a reading and understanding of the preceding detailed description. It is intended that the invention be construed as including all such modifications and alterations insofar as
5 they come within the scope of the appended claims or the equivalents thereof.

Having thus described the preferred embodiments, the invention is now claimed to be:

1. A cardiac assist apparatus comprising:
5 a blood pump;
a drive unit for driving the blood pump;
a power supply for supplying power to the drive unit;
a frequency sensor that senses a rotational speed of the blood pump;
a current sensor that senses an average direct current waveform of
10 the drive unit;
a power supply voltage sensor that senses a power supply voltage;
and
a blood pump controller that receives data from the frequency
sensor, current sensor, and the power supply voltage sensor and controls operation
15 of the blood pump in response thereto.
2. The cardiac assist apparatus as set forth in claim 1, wherein the
controller estimates a drive unit input power, a flow rate, a patient heart rate,
pressure and a desired flow rate.
20
3. The cardiac assist apparatus as set forth in claim 1, further
comprising a drive unit winding commutation circuit for relaying the desired flow
rate to the drive unit motor.
- 25 4. The cardiac assist apparatus as set forth in claim 1, wherein the drive
unit includes a brushless DC motor.
5. The cardiac assist apparatus as set forth in claim 1, wherein the
power supply includes at least one rechargeable battery.
30
6. The cardiac assist apparatus as set forth in claim 1, wherein the
frequency sensor includes one of a back EMF, Hall and optical sensor.
7. The cardiac assist apparatus as set forth in claim 1, wherein the
35 controller based on the input information, calculates:
a drive unit input power;

a heart rate;
a pump flow rate; and,
a pressure differential.

5 8. The cardiac assist apparatus as set forth in claim 7, wherein the
controller calculates a new pump flow rate based on the calculated heart rate.

 9. The cardiac assist apparatus as set forth in claim 8, wherein the new
flow rate is within a pre-determined margin.

10

 10. The cardiac assist apparatus as set forth in claim 9, wherein the
margin includes flow rates corresponding to preset maximum and minimum
heartbeats per minute.

15 11. A method of controlling blood flow with a blood pump comprising:
sensing a current waveform of a drive motor of the blood pump;
sensing an input voltage waveform to the drive motor;
sensing a rotational frequency waveform of the drive motor; and
controlling operation of the blood pump in response to the sensing
20 steps.

 12. The method as set forth in claim 11, further including:
calculating a motor input power;
calculating a heart rate;
25 calculating a pump flow rate;
calculating a pump pressure differential; and,
calculating a required pump flow based on current physiological
conditions.

30 13. The method as set forth in claim 12, further including:
analyzing a pump performance to verify that the pump is operating
within predetermined conditions.

 14. The method as set forth in claim 12, wherein the step of calculating
35 the motor input power uses the equation:

$$S_{elec} = v * I$$

where S_{elec} is an average electrical power of the motor in a time interval T , v is the measured voltage, and I is an average current over the time interval T .

15. The method as set forth in claim 14, wherein the step of calculating the heart rate includes analyzing one of the current waveform, input power, rotational frequency, pressure differential and pump flow waveform for a fundamental frequency.

16. The method as set forth in claim 12, wherein the step of calculating the pump pressure differential includes using one of the equation:

$$P_{\text{norm}} = \psi(Q_{\text{norm}})$$

and a look up table, where $P_{\text{norm}} = P/\sigma * \omega^2$, $Q_{\text{norm}} = Q/\omega$, and ω is the pump rotational speed, σ is the blood density.

17. The method as set forth in claim 12, wherein the step of calculating the required pump flow includes one of the equations:

$$Q_{\text{target}} = C_1 * \text{HR} + C_2; \text{ and,}$$

$$Q_{\text{target}} = f(M);$$

where Q_{target} is the desired flow rate, C_1 and C_2 are constants determined by patient heart condition and size, $M = \text{HR}/P$ where P is the pressure and HR is the heart rate.

18. The method as set forth in claim 12, wherein the step of calculating the required pump flow includes tracking the heart rate and basing the flow rate on the heart rate.

19. The method as set forth in claim 13, wherein the predetermined conditions include:

- a minimum flow rate;
- a maximum flow rate;
- a minimum pulsatility;
- a minimum pump rotational speed; and,
- a maximum pump rotational speed.

20. The method as set forth in claim 12, further including reverting to a pre-selected default pump rotational speed in the event of a controller failure.

21. The method as set forth in claim 12, further including reverting to a pre-selected default motor input power in the event of a controller failure.

5 22. The method as set forth in claim 12, further including reverting to a pre-selected default PWM duty cycle in the event of a controller failure.

23. The method as set forth in claim 19 wherein the safety conditions include:

10 absolute minimum flow rate, and
relative minimum flow rate.

24. The method as set forth in claim 23 comprising the further step of calculating the relative minimum flow rate as

15
$$Q_{rel\ min} = A * (\omega - \omega_0)^n.$$

25. The method as set in claim 23, further including reverting to a pre-selected default power level decrease in response to detecting ventricular suction.

20 26. The method as set forth in claim 12, wherein the step of calculating the pump flow includes using one of the equation:

$$Q = \phi(S/\omega^2)$$

and a look up table, where $S = V * I$, S is average electrical power, V is motor driven bus voltage, I is motor average current within a certain time interval, and ω is the
25 pump rotational speed.

1/8





Fig. 1



HR (BPM)	60	90	120	60	90	120	60	90	120
ΔP (mmHg)	120	120	120	90	90	90	60	60	60
M	.5	.75	1.0	.67	1.0	1.33	1.0	1.5	2.0

Fig. 2

2/8




Fig. 3

3/8




Fig. 4

4/8




Fig. 5A

5/8




Fig. 5B

6/8




Fig. 6

7/8




Fig. 7

8/8





Fig. 8

INTERNATIONAL SEARCH REPORT

In  national Application No

PCT/US 01/08776

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61M/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 711 753 A (CLARK RICHARD E ET AL) 27 January 1998 (1998-01-27) column 11, line 49 -column 13, line 7 column 14, line 45 - line 47 figures 13,14	1,4,6,11
A	WO 99 17819 A (MICROMED TECHNOLOGY INC) 15 April 1999 (1999-04-15) page 5, line 14 -page 6, line 11 page 7, line 10 -page 9, line 9 page 15, line 20 - line 28 figures 3,6	1,11
A	DE 196 34 180 A (NTN TOYO BEARING CO LTD) 27 February 1997 (1997-02-27) column 2, line 57 -column 3, line 58 column 4, line 52 -column 5, line 49 figures 1-5	1,11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 October 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Schönleben, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 01/08776

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5711753	A	27-01-1998	US 6162167 A	19-12-2000
			AU 699959 B2	17-12-1998
			AU 3513495 A	10-11-1995
			AU 718838 B2	20-04-2000
			AU 6599798 A	02-07-1998
			CA 2165166 A1	26-10-1995
			EP 0708664 A1	01-05-1996
			JP 9502375 T	11-03-1997
			WO 9528185 A1	26-10-1995
WO 9917819	A	15-04-1999	AU 9787498 A	27-04-1999
			EP 1019117 A1	19-07-2000
			TW 404842 B	11-09-2000
			WO 9917819 A1	15-04-1999
			US 6183412 B1	06-02-2001
DE 19634180	A	27-02-1997	JP 9056812 A	04-03-1997
			DE 19634180 A1	27-02-1997
			US 6129660 A	10-10-2000